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ABSTRACT
In human, mutations of the protocadherins FAT4 and DCHS1 result in
Van Maldergem syndrome, which is characterised, in part, by
craniofacial abnormalities. Here, we analyse the role of Dchs1-Fat4
signalling during osteoblast differentiation in mouse. We show that
Fat4 and Dchs1 mutants mimic the craniofacial phenotype of the
human syndrome and that Dchs1-Fat4 signalling is essential for
osteoblast differentiation. In Dchs1/Fat4 mutants, proliferation of
osteoprogenitors is increased and osteoblast differentiation is
delayed. We show that loss of Dchs1-Fat4 signalling is linked to
increased Yap-Tead activity and that Yap is expressed and required
for proliferation in osteoprogenitors. In contrast, Taz is expressed in
more-committed Runx2-expressing osteoblasts, Taz does not
regulate osteoblast proliferation and Taz-Tead activity is unaffected
in Dchs1/Fat4 mutants. Finally, we show that Yap and Taz
differentially regulate the transcriptional activity of Runx2, and that
the activity of Yap-Runx2 and Taz-Runx2 complexes is altered in
Dchs1/Fat4 mutant osteoblasts. In conclusion, these data identify
Dchs1-Fat4 as a signalling pathway in osteoblast differentiation,
reveal its crucial role within the early Runx2 progenitors, and identify
distinct requirements for Yap and Taz during osteoblast
differentiation.
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INTRODUCTION
How signalling networks integrate to control osteoblast proliferation
and differentiation to form bone during embryonic development and
postnatally is a fundamental question. Bones are not only essential
for locomotion but provide support and protection of internal
structures and play crucial roles in many aspects of physiology.
Bones are reservoirs for phosphorous and calcium, are important for
glucose metabolism, house the haematopoietic system and are
essential for the function of the renal andmale reproductive systems.
Bone is continually remodelled throughout life and de-regulation
can result in bone disorders such as osteoporosis, the most frequent
bone disorder contributing to significant morbidity in the elderly.
Osteogenic differentiation is initiated within mesenchymal or
endochondral precursors through the expression of the
transcription factor Runx2, which is essential for osteoblast
differentiation (Komori et al., 1997; Otto et al., 1997). Runx2
directly regulates the expression of the transcription factor osterix
(Sp7), the cell cycle inhibitor p21 (Cdkn1a), alkaline phosphatase,
and the matrix protein Bglap (bone γ-carboxyglutamate protein,
also known as osteocalcin), to control cell differentiation along the
osteogenic pathway (Westendorf et al., 2002).
Recently, loss-of-function mutations in the protocadherins
DCHS1 and FAT4 have been shown to be responsible for Van
Maldergem syndrome, which is, in part, characterised by
craniofacial defects including enlarged fontanelles and under-
development of the maxilla (Cappello et al., 2013; Mansour et al.,
2012; Neuhann et al., 2012; Zampino et al., 1994). In some patients,
a generalised osteopenia has also been reported (Mansour et al.,
2012). Dchs1 and Fat4 typically act as a ligand-receptor pair (Mao
et al., 2011, 2015, 2016; Zakaria et al., 2014; Bagherie-Lachidan
et al., 2015) and this new data indicates that they may be crucial for
the maintenance of skeletal integrity in humans and potentially
identifies a new signalling pathway in osteogenic differentiation.
Ds and Fat, the Drosophila homologues of vertebrate Dchs1 and
Fat4, respectively, have two key functions during development: they
inhibit tissue growth and regulate planar cell polarity (PCP), the
coordinated polarised cell behaviour within a plane of a tissue
(Matis and Axelrod, 2013; Irvine and Harvey, 2015). Examples of
PCP include the polarised orientation of cellular structures, such as
the bristles and hairs on the Drosophilawing and abdomen. Fat and
Ds inhibit tissue growth via inhibition of the Hippo pathway, which
regulates the activity of the Yorkie/Scalloped transcriptional
complex to control cell proliferation, survival and differentiation
(Misra and Irvine, 2018). In the absence of Fat/Ds, Yorkie signalling
is increased resulting in overgrowth and dysplasia of the
imaginal discs.
There is now clear evidence for conservation of Dchs1-Fat4
regulation of PCP in vertebrates. In mice, Dchs1-Fat4 regulates PCP
ensuring orientated and collective cell behaviours during elongation
of the developing kidney tubules, development of the sternum and
migration of the facial branchiomotor neurons (Saburi et al., 2008;
Mao et al., 2016; Zakaria et al., 2014). There is also evidence in
vertebrates for regulation of the Yorkie homologues, Yap (YES-
associated protein; Yap1) and Taz (transcriptional coactivator with
PDZ-binding motif; Wwtr1). Loss of Dchs1-Fat4 signalling in the
developing mouse cerebral cortex and heart results in increased
proliferation that can be rescued by downregulation of Yap
(Cappello et al., 2013; Ragni et al., 2017). Similarly, loss of Fat4
in the chick neural tube results in decreased phosphorylation of Yap
(pYap), the inactive form of Yap, together with increased
proliferation of a subset of neurons, again implicating loss of Fat4
signalling with activation of Yap (Van Hateren et al., 2011). In the
mouse kidney, Fat4 regulation of Yap/Taz intracellular localisation
within nephrogenic precursors has also been observed by some
(Das et al., 2013) but not by other researchers (Bagherie-Lachidan
et al., 2015; Mao et al., 2015).Received 9 February 2019; Accepted 20 June 2019
1Centre for Craniofacial and Regenerative Biology, Faculty of Dentistry, Oral &
Craniofacial Sciences, King’s College London, Floor 27, Guy’s Tower, London SE1
9RT, UK. 2Comparative Biomedical Sciences, Royal Veterinary College, Camden,
London, NW1 0TU, UK. 3Waksman Institute and Department of Molecular Biology
and Biochemistry, Rutgers University, Piscataway, NJ 08854, USA.
*These authors contributed equally to this work
‡Author for correspondence (philippa.francis-west@kcl.ac.uk)
I.C.-E., 0000-0003-2967-4554; P.F.-W., 0000-0001-5179-5892
1
© 2019. Published by The Company of Biologists Ltd | Development (2019) 146, dev176776. doi:10.1242/dev.176776
D
E
V
E
LO
P
M
E
N
T
Both PCP and Yap/Taz have been implicated in osteogenic
development. The Fz-PCP pathway controls the orientation of cell
divisions in the osteoblastic cell line Saos-2 (Galea et al., 2015), and
Yap/Taz can modulate the activity of Runx2. Specifically, it has
been shown that Taz can potentiate the activity of the osteoblast
determination transcription factor Runx2 to promote osteoblast
differentiation, and inhibit expression of PPARγ, which controls
adipocyte fate (Cui et al., 2003; Hong et al., 2005; Pan et al., 2018).
In contrast, Yap can inhibit the ability of Runx2 to activate specific
transcriptional targets such as TGFβ receptor type 1 and the matrix
protein Bglap (Zaidi et al., 2004). Activation of Yap/Taz in response
to mechanotransduction signals induced by the actin cytoskeleton
and matrix stiffness also promotes osteoblast differentiation from
mesenchymal stem cells (Dupont et al., 2011).
Here, using genetic mouse models, we determine the function,
and mechanisms of action, of Dchs1-Fat4 signalling during
osteogenic development and identify a new signalling pathway
that is required intrinsically during osteoblast differentiation. We
show that Dchs1 and Fat4 mouse mutants are characterised by an
under-development of the cranial skeletal structures, as in Van
Maldergem patients. We show that one of the key roles of Dchs1-
Fat4 signalling is within the early Runx2-positive (Runx2+ve)
osteogenic progenitors – in the absence of either Dchs1 or Fat4,
proliferation is increased and this is coupled with delayed
progression along the differentiation pathway. In vitro analysis
revealed that this is linked with increased activity of Yap-Tead, but
not Taz-Tead, activity. Additionally, loss of Dchs1-Fat4 signalling
results in increased activity of the Runx2-TGFβR1 reporter and
decreased activity of the generic Runx2 and Runx2-p21 reporters,
which we show are differentially regulated by Yap and Taz.
RESULTS
Defective skeletal development in Dchs1 and Fat4 mutants
VanMaldergem syndrome patients are characterised by pronounced
craniofacial skeletal defects including enlarged fontanelles
(Zampino et al., 1994). To determine potential roles of Fat4 and
Dchs1 during skeletogenesis, wild-type, heterozygous, Fat4−/− and
Dchs1−/− postnatal day (P) 0 mice were first analysed by micro-
computed tomography (μ-CT) imaging and Alizarin Red/Alcian
Blue staining to identify alterations in skeletal development. The
size of different bones, specifically the mandible, frontal, parietal,
interparietal and palatine bones, within the craniofacial complex
was also determined.
This analysis revealed that all craniofacial bones are specified
appropriately but all bones analysed are significantly smaller in
Dchs1−/− and Fat4−/− mutants (Fig. 1; Fig. S1A; Tables S1, S2;
Dchs1+/+ n=3, Dchs1−/− n=4, P<0.01; Fat4+/+ n=3, Fat4−/− n=3,
P<0.01). Thus, the face is smaller and the cranial vault is
characterised by larger fontanelles (Fig. 1A, Fig. S1A). This is
not due to a developmental delay as the body and head size ofFat4−/−
and Dchs1−/− mutants are not significantly different from their
heterozygous and wild-type littermates (Mao et al., 2011). Both
neural crest-derived (frontal, mandible, palatine) and mesodermally
derived (parietal and interparietal) bones are affected, indicating that
the decreased ossification is not related to tissue origin. Heterozygous
mice had no overt phenotype (Fig. S1A,B; Table S2; Dchs1+/− n=4,
Fig. 1. Dchs1 and Fat4 are required for cranial skeletal development. (A) μ-CT scans of wild-type (WT; Dchs+/+ n=3; Fat+/+ n=3), Dchs1−/− (n=4), Fat4−/−
(n=3), Dermo1Cre; Fat4f/− (n=3) P0 pups. The control Dermo1Cre; Fat4f/+ (n=3), which have no phenotype, are not shown. The upper row shows sagittal views of
the skull and face, the middle row shows the skull cap and the lower row shows the cranial base and upper jaw. (B-G) Quantification of the relative size of the skull
cap (B) and individual bones (C-G) in Dchs1−/−, Fat4−/− and Dermo1Cre; Fat4f/−mutants compared with their wild-type and controlDermo1Cre; Fat4f/+ littermates,
respectively. Within each control group (wild type and control Dermo1Cre; Fat4f/+) the average measurement was standardised to 1. In some CT images,
background ‘noise/dots’ between the bones in the CT scans may have been removed for clarity. bo, basioccipital; bs, basisphenoid; f, frontal; i, interparietal; m,
maxilla; md, mandible; p, parietal; pa, palatine; pm, premaxilla bones. Unpaired two-tailed Student’s t-test: *P<0.05; **P<0.01; ***P<0.001. Error bars represent
s.e.m. Scale bars: 1 mm.
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Fat4+/− n=4). Quantification of the bone mineral density within the
frontal, parietal and interparietal bones revealed no significant
difference inDchs1−/− andFat4−/−mutants comparedwith wild-type
controls (Fig. S1C; Tables S3, S4; Dchs1−/− n=4, Fat4−/− n=3).
Alizarin Red andAlcian Blue staining revealed that Fat4−/−/Dchs1−/−
double mutant mice had palatine and mandible defects that were
identical to those of the Fat4−/− and Dchs1−/− single mutants,
suggesting that they act as a dedicated receptor-ligand pair as in
many other regions of the embryo (Fig. S1D; n=3;Mao et al., 2011).
To exclude the possibility that changes in craniofacial bone
development are secondary to alterations in development of soft
tissues such as the eye, brain and skeletal muscle, Dermo1Cre/+;
Fat4f/−, Dermo1Cre/+; Dchs1f/− andMesp1Cre/+; Dchs1f/f mice were
generated. In the Dermo1Cre lines, Fat4 and Dchs1 expression are
silenced in both the mesodermal- and neural crest-derived pre-
osteoblast progenitors whereas inMesp1Cre/+; Dchs1f/fmice,Dchs1
is silenced in the mesoderm that gives rise to the parietal and part of
the interparietal bone. We found that in Dermo1Cre/+; Fat4f/− and
Dermo1Cre/+; Dchs1f/− mice there is a significant reduction in the
size of all the craniofacial bones analysed (Fig. 1; Fig. S1E;
Tables S1, S2, S8; Dermo1Cre/+; Fat4f/− n=3, P<0.05; Dermo1Cre/+;
Dchs1f/− n=3, P<0.005). Likewise, in P0Mesp1Cre/+; Dchs1f/f mice,
there was a significant reduction in the size of the parietal and
interparietal bones where the Cre-recombinase is expressed,
compared with control mice (Fig. S1F; Table S5; Mesp1Cre/+;
Dchs1f/f n=3, P<0.01). As internal controls in P0Mesp1Cre/+; Dchs1f/f
mice, the neural crest-derived palatine and frontal bones, where the
Cre-recombinase is not expressed, were also analysed. As would be
expected, these bones were not affected (Fig. S1F).
As Van Maldergem patients show a generalised osteopenia, the
appendicular skeleton, which develops via endochondral
ossification, was also examined. Analysis of the femur revealed
that there is a decrease in several bone parameters [BV/TV
(mineralised bone volume/total bone volume), trabeculae number,
cortical thickness] in Dchs1−/− mutants (Fig. 2; Table S6; Dchs+/+
n=5, Dchs1−/− n=7; BV/TV P<0.05; trabeculae number P<0.05;
cortical thickness-midshaft, P<0.05; cortical thickness-metaphysis
P<0.05). In contrast, in Fat4−/−mutants, therewas only a significant
decrease in cortical thickness at the midshaft (Fig. 2; Table S6;
Fat4+/+ n=5, Fat4−/− n=5, P<0.01). Therefore, the bone defects in
Dchs1−/− and Fat4−/−mutants also encompass at least some aspects
of endochondral bone development.
Dchs1-Fat4 function in the osteoblast progenitors
To analyse bone development further in Dchs1−/− and Fat4−/−
mutants, we next determined when the craniofacial skeletal
abnormalities are detectable, and then determined which
osteogenic cell populations express Dchs1 and Fat4 at these
stages of development.
Alizarin Red and Alcian Blue staining of embryonic day (E) 15.5
and E16.5 Dchs1 mutant embryos revealed that the mandible and
palatine bones are visibly smaller at E15.5 and E16.5, respectively
(Fig. 3). Thus, the defects start to arise during the very early phases
of bone development. In situ hybridisation analysis at these stages
revealed that Fat4 and Dchs1 are expressed in both the osteoblast
precursors and within the more differentiated osteoblasts (Fig. 4A).
To determine whether osteoblast differentiation is altered, the
expression of the osteogenic markers Runx2, osterix, osteopontin
(Spp1) and Bglap, which characterise different stages of osteoblast
differentiation, were analysed in tissue sections through the
developing palatine and calvaria bones at E15.5 and E16.5. This
analysis included both the parietal and frontal calvaria bones, which
have distinct embryonic tissue origins, and proliferative and
osteogenic potential (Jiang et al., 2002; Xu et al., 2007; Quarto
et al., 2010). In addition, sections were examined for alkaline
phosphatase (ALP) activity, which is highly expressed in early
osteoblast progenitors, and stained with Alizarin Red, which binds
mineralised matrix.
These analyses revealed that Runx2, osterix, osteopontin and
Bglap are expressed appropriately within the developing bones in
Dchs1−/− and Fat4−/− mutants (Fig. 4C; Runx2 and osterix
immunostaining: E15.5, wild type n=7, Fat4−/− n=4, Dchs1−/−
n=3; E16.5, wild type n=7, Fat4−/− n=4; Dchs1−/− n=3; Bglap
in situ hybridisation: E15.5/16.5, wild type n=8, Fat4−/− n=4;
Dchs1−/− n=4; osteopontin in situ hybridisation: E15.5/16.5 wild
type n=10, Fat4−/− n=5, Dchs1−/− n=5). ALP activity and
mineralisation levels also appeared to be comparable: the latter is
consistent with the µ-CT density measurements at P0 (Fig. 4B;
Fig. 2. Dchs1 and Fat4 are also required for
appendicular skeletal development. (A) μ-CT scans
of wild-type (WT; n=10), Dchs1−/− (n=7) and Fat4−/−
(n=5) P0 pups showing sagittal views of the femur
together with transverse cross-sections of the cortical
bone at the levels indicated by the dashed lines. In
some CT images, background ‘noise/dots’ may have
been removed for clarity. (B-E) Quantification of the
relative BV/TV (B), trabeculae number (C), cortical
thickness at the midshaft (D) and metaphyses (E)
where the average measurement of the control group
was standardised to 1. Unpaired two-tailed Student’s
t-test: *P<0.05; **P<0.01. ns, not significant. Error
bars represent s.e.m. Scale bars: 0.5 mm.
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Fig. S1C; ALP activity: E15.5, wild type n=9, Fat4−/−n=4,Dchs1−/−
n=4; E16.5 wild type n=10; Fat4−/− n=5, Dchs1−/− n=5;
mineralisation: E15.5, wild type n=7, Fat4−/− n=3, Dchs1−/− n=4;
E16.5, wild type n=7, Fat4−/− n=5, Dchs1−/− n=4). However, there
was a clear expansion in the numbers of Runx2+veosterix−ve cells, the
osteogenic progenitors, in both the palatine and calvaria bones
(Fig. 4C). This expansion is also apparent by comparing the domains
of ALP activity (Fig. 4B). Quantification of the number of
Runx2+veosterix−ve cells within the Runx2+ve osteoprogenitor
populations revealed that there was indeed a significant increase in
the percentage of the Runx2+veosterix−ve progenitors (Fig. 4D and
data not shown; E15.5, Fat4+/+ n=3, Fat4−/− n=3; palatine, P<0.05;
frontal, P<0.05; E16.5, Fat4+/+ n=3, Fat4−/− n=3; palatine, P<0.01;
frontal, P<0.05; parietal, P<0.01).
Dchs1 and Fat4 regulate osteoblast proliferation, survival
and differentiation
To determine whether changes in cell proliferation and/or cell
survival contribute to the expansion of the osteoblast precursors,
cells in the S and M phase of the cell cycle were identified by
injection of 5-ethynyl-2′-deoxyuridine (EdU) and phospho-histone
3 immunostaining, respectively. Cells undergoing apoptosis were
identified by immunolabelling for activated caspase 3.
These analyses revealed that proliferation within the Runx2+ve
cell population is significantly increased between E15.5 and E18.5
(Fig. 5A,B; Fig. S2A,B; E15.5 and E16.5: Fat4−/− and Dchs1−/−
palatine, P<0.01; frontal, P<0.05; E16.5: Fat4−/− parietal, P<0.05;
E18.5: Fat4−/− andDchs1−/− palatine, P<0.05; frontal, P<0.05; n=3
wild type and 3 mutants for each genotype and stage analysed). This
increase in proliferation included the Runx2+veosterix+ve
populations (Fig. 5A,B; P<0.05; palatine and frontal bones
analysed). There was also a significant increase in proliferation
associated with the trabecular bone of the femur, an endochondral
bone, in Dchs1−/−, but not Fat4−/−, mutants. This is consistent with
the differential requirements of Dchs1 and Fat4 within the
endochondral bones that were observed in the µ-CT analyses
(Fig. 2; Dchs1 P<0.05 and data not shown). In contrast, no or very
few cells undergoing apoptosis were identified in either wild-type or
mutant embryos at E16.5 (data not shown; wild type n=3, mutant
n=3) but a significant increase in apoptosis within the osteogenic
progenitors was observed at E18.5 (Fig. S2; n=3 wild type and 3
mutants; Dchs1−/− and Fat4−/− palatine, P<0.01; frontal, P<0.05).
This increased proliferation and expansion of the cell numbers in
the osteogenic progenitor pool is inconsistent with the under-
development of the bones, indicating that it may be coupled with
delayed differentiation. Alternatively, Dchs1-Fat4 may also be
required within the terminally differentiating osteoblasts, where
they are also expressed, and/or there may be increased osteoclast
activity in the mutants. To investigate these possibilities, E16.5
embryos were labelled sequentially with calcein and Alizarin Red to
identify the bone mineralisation front and osteoclast activity was
analysed by tartrate-resistant acid phosphatase (TRAP) staining. In
Dchs1−/− embryos, the domain of calcein labelling was
significantly smaller in the frontal and parietal bones compared
with wild-type littermates (Fig. 5C; Fig. S5; n=3 each for Dchs1+/+
and Dchs1−/−, P<0.001). In contrast, no observable differences in
TRAP staining were identified (n=3; Fat4−/− data not shown).
These data suggest that the deficiency in bone architecture in Dchs1-
Fat4 mutants is coupled with delayed osteoblast differentiation.
To determine whether Fat4 and Dchs1 are required within the
terminally differentiated osteoblasts, Fat4 and Dchs1 expression
was deleted using the osteocalcin (Bglap)-Cre line (OC-Cre).
Cranial development was compared between the controls,
OC-CreCre/+; Fat4f/+ and OC-CreCre/+; Dchs1fl+, and the OC-
CreCre/+; Fat4f/− or OC-Cre/+; Dchs1f/− mutants. In OC-CreCre/+;
Fat4f/− pups, no significant differences in the development of the
skull or facial bones were detected compared with the controls
(Fig. S3; Table S5; OC-CreCre/+; Fat4f/+ n=3, OC-CreCre/+; Fat4f/−
n=5). In contrast, a minor decrease in bone volume was observed in
the OC-CreCre/+; Dchs1f/− mice compared with the controls (Fig.
S3; Table S5; OC-CreCre/+; Dchs1f/+ n=4, OC-CreCre/+; Dchs1f/−
n=5; whole skull: P<0.05; frontal: P<0.01; parietal: P<0.05;
palatine: P<0.05). The decrease in the size of the bones was,
however, clearly less than that observed in Dchs1 mutants (Fig. 1),
indicating that the major roles of Dchs1 occur within the
osteoprogenitors.
Dchs1- Fat4 signalling regulates Yap and Taz activity
In the developing cerebral cortex and heart, loss of Fat4 signalling is
linked to increased Yap-dependent proliferation (Cappello et al.,
2013; Ragni et al., 2017). To determine whether similar processes
occur in bone, primary osteoblasts from Fat4+/+ and Fat4−/−mutant
P0 calvaria were transfected with either the Yap/Taz-Tead luciferase
reporter construct, which measures Tead binding activity, or the
control reporter containing mutated Tead-binding sites. These
primary cultures comprise more than 97% Runx2+ve cells on day 1
of culture (Fig. 6A) and express Bglap, indicative of terminal
osteoblast differentiation, at later time points (Fig. 6A,B). In Fat4−/−
mutant cultures, however, there was a significant increase in the
number of EdU-labelled cells (Fig. 6E; P<0.001) and an associated
decrease in the percentage of Bglap-expressing cells at day 3 of
culture (Fig. 6A,B; Fat4+/+ n=3, Fat4−/− n=3, P<0.001). Thus, the
Fig. 3. Development of the cranial bones in Dchs1 mutants. (A-D) Alizarin
Red and Alcian Blue staining of E15.5 and E16.5 wild-type and Dchs1−/−
embryos; bone and cartilage are stained red and blue, respectively.
(A,C) Cranial views of the cranial base and upper jawat E15.5 (n=2) and E16.5
(n=3), respectively (the cranial vault has been removed); the right-hand
side image is an enlarged image of the boxed area showing the palatine,
basisphenoid and pterygoid bones. (B,D) Sagittal views of the mandible and
Meckel’s cartilage within the lower jaw at E15.5 and E16.5, respectively;
Meckel’s cartilage is indicated by arrows in B. a, angular process; ba,
basisphenoid; bo, basioccipital; co, condylar process; cor, coronoid process;
mc, Meckel’s cartilage; pa, palatine; pt, pterygoid bones. Scale bars: 100 μm.
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in vitro cultures mimic in vivo osteogenesis. Using these cultures we
found that the activity of the Yap/Taz-Tead, but not the control,
luciferase reporter was significantly increased in Fat4−/− osteoblasts
(Fig. 6C; Fat4+/+ n=3; Fat4−/− n=9, P<0.005). Similarly, activity of
the Yap/Taz-Tead reporter was increased in Dchs1−/− primary
osteoblasts relative to either wild type or Dchs1+/− controls (wild
type n=6, Dchs1−/− n=6, P<0.05; data not shown).
To help rule out the possibility that small differences in the
starting cell population may contribute to the increased Yap/Taz-
Tead signalling observed, we also assessed the effect of either Fat4
or Dchs1 knockdown in the osteogenic cell line MC3T3-E1. Again,
we found that disruption of Fat4-Dchs1 signalling led to increased
Yap/Taz-Tead reporter activity (Fig. 6C; n=3; Fat4 shRNA, P<0.01;
Dchs1 shRNA, P<0.05). We also confirmed that the ‘Yap/Taz’
targets Ctgf (Ccn2), Cyr61 (Ccn1) and Ankrd1 were increased by
qPCR of Fat4 shRNA-treated MC3T3-E1 cells (n=3, P<0.005).
Finally, we confirmed that gain of function of Fat4 is sufficient to
decrease Yap/Taz-Tead reporter activity in both primary cultures
from wild-type and Fat4−/− mice and in the MC3T3-E1 cell line
(Fig. 6D; Fat4+/+ n=3, P<0.05; Fat4−/− n=3, P<0.001; Fat4
overexpression in MC3T3-E1 cells: control n=5, Fat4 full length
n=4, P<0.05). Collectively, the data indicate that Dchs1-Fat4
signalling directly regulates Yap/Taz-Tead activity in osteoblasts.
Yap is the key regulator of Tead activity and proliferation
within developing osteoblasts
To determine whether the increased Yap/Taz-Tead luciferase
reporter activity in mutant cells is due to increased Yap and/or
Fig. 4. Dchs1 and Fat4 regulate the number of osteoblast progenitors. (A) In situ hybridisation of Fat4 and Dchs1 expression in an E16.5 palatine (upper two
rows) and frontal bone (lower row). Control in situ hybridisation on Fat4 andDchs1mutant tissue are shown on the right-hand side. (B) Frontal sections through the
whole palatine and osteogenic front of the frontal bone showing Hematoxylin & Eosin (H&E) staining, mineralisation by Alizarin Red staining and alkaline
phosphatase activity. For the ALP assay, a high-power view through the osteogenic fronts is shown for the palatine (boxed region of above lower power image).
The length of the osteogenic fronts within the frontal bone is indicated by the arrows. (C) The osteogenic fronts of palatine and frontal bones in wild type and
Fat4−/− mutants showing Runx2 (magenta) and osterix (yellow) immunostaining and in situ hybridisation of osteopontin and Bglap where the blue staining
indicates RNA expression. In A-C, the bones are outlined in white and the mineralised areas of the bone are outlined in yellow; the osteogenic progenitors are
located between these lines. Number of biological replicates for each analyses stated in main text. (D) Quantification of the percentage of Osx−ve (purple)
and Osx+ve (yellow) cell populations within the total Runx2 population of E16.5 palatine, frontal and parietal bones of Fat4+/+ (n=3 biological replicates)
and Fat4−/− (n=3) mutants. Unpaired two-tailed Student’s t-test: *P<0.05; **P<0.01. Error bars represent s.e.m.
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Taz activity, Yap and Taz expression was knocked down in
Fat4−/− cells and the effect on the activity of the Yap/Taz-Tead
luciferase reporter was measured. Both Yap and Taz shRNA
knockdown significantly, and specifically, reduced Yap and
Taz mRNA expression, respectively (Fig. 6F); however, only
knockdown of Yap significantly reduced the activity of the
‘Yap/Taz-Tead’ luciferase reporter in wild-type and Fat4−/−
osteoblasts (Fig. 6E; P<0.01). In contrast, knockdown of Taz
had no significant effect (Fig. 6E). Thus, Yap and Taz have
distinct effects on the Yap/Taz-Tead reporter within the
osteoblasts.
During the above studies we also observed that Taz mRNA
expression is decreased in Fat4−/− osteoblasts (Fig. 6F) and
confirmed this regulation in MC3T3-E1 cells following
knockdown of Fat4 (Fig. 6F). Furthermore, our analysis of the
Taz+/− and Taz−/− skeletal phenotype versus wild-type counterparts
had revealed that a 50% reduction in Taz expression results in
under-development of the cranial bones (Fig. S4A,B; Table S7).
This raised the possibility that a decrease in the levels of Taz protein
in Fat4−/− osteoblasts may contribute to the mutant phenotype.
To examine this possibility, we carried out immunolocalisation
analysis of Taz expression within the developing bones of wild type
Fig. 5. Dchs1-Fat4 regulation of osteoblast proliferation and differentiation. (A) Immunostaining of osteogenic fronts of palatine and frontal bones in E15.5
wild-type and Fat4−/− embryos showing osterix expression (yellow) and EdU labelling of proliferating cells (magenta). DAPI staining (grey) is also shown.
The boundary of the osteogenic front was identified by Runx2 staining (not shown) and is indicated by the dashed blue line. (B) Quantification of the
number of proliferating cells (EdU labelled) within the Runx2+ve osteoprogenitors (i.e. both the Runx2+veosterix−ve and Runx2+veosterix+ve cells) and within
Runx2+veosterix+ve osteoprogenitors in the frontal and palatine bones. (C) Sequential calcein (yellow) and Alizarin Red (magenta) labelling of E16.5 osteogenic
fronts in wild-type andDchs1−/− frontal and parietal bones (n=3 for each genotype). For B, within each control group the average measurement was standardised
to 1. n=3 biological replicates for each genotype and each analysis. Unpaired two-tailed Student’s t-test: *P<0.05; **P<0.01; ***P<0.005. ns, not significant.
Error bars represent s.e.m. Scale bars: 100 µm.
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and Dchs1−/− mutants. We found that Taz expression is highest
within the osteoblasts (Runx2+veosterix+ve) adjacent to the
mineralisation front and could not identify any obvious
differences in either the level or domain (nuclear/cytoplasmic) of
Taz expression in Dchs1−/− mutants (Fig. 7B). We also
quantitatively determined the total levels of Taz protein in
Fig. 6. Dchs1 and Fat4 regulate Yap
activity. (A) Cultures of primary calvaria
osteoblast cells from wild type (n=3
biological replicates) and Fat4−/− (n=3)
P0 mutants immunostained for Bglap
(yellow), and co-stained for Runx2
(magenta). (B) Quantification of the
percentage of Bglap+ve cells at days 3
and 7 of culture. (C) Analysis of Yap/Taz-
Tead reporter activity, and its control
reporter, in primary Fat4+/+ and Fat4−/−
calvaria osteoblast cells, and in the
MC3T3 cell line in which Dchs1 and Fat4
expression has been knocked down with
shRNA constructs. (D) Analysis of Yap/
Taz-Tead reporter activity in primary
Fat4+/+ and Fat4−/− calvaria osteoblast
cells, and in the MC3T3 cell line following
transfection of a vector encoding full-
length Fat4. (E) Alteration in Yap/Taz-
Tead reporter activity and proliferation in
Fat4+/+ and Fat4−/− calvaria osteoblasts
following knockdown of either Yap or
Taz. (F) qPCR analyses. Left and centre:
Relative levels of Yap and Taz mRNA in
Fat4−/−osteoblasts compared with wild-
type expression levels and validation of
effective and specific knockdown of Yap
and Taz using the shRNA constructs.
Right: relative mRNA levels of Taz, Bglap
and p21 in MC3T3 cells transfected
with shRNA for Fat4, compared with
normalised levels (to 1) in control cells
transfected with scrambled shRNA.
For C-F, data points indicate each
independent biological experiment i.e.
n≥3, each with 2-3 technical replicates.
Within each control group the average
measurement was standardised to
100% (1 on graphs). Statistical analyses:
unpaired two-tailed Student’s t-tests for
two group comparisons in B,C (left), and
D (right), (significance shown in black);
for three or more group comparisons,
ordinary one-way ANOVA tests
(significance shown in purple) were
applied in C (right), D (left), E,F (left),
followed by post-hoc analyses for
multiple comparisons (significance
shown in black) using Dunnett’s tests in C
(right), and F (left) and Tukey’s tests in D
(left), and E; in F, one sample t-test with a
theoretical mean of 1 (relative mRNA
expression value in control cells) for each
set of qPCR data used. Significance:
*P<0.05, **P<0.01, ***P<0.001,
****P<0.0001. ns, not significant. Error
bars represent s.e.m. Scale bar: 50 µm.
scr, scrambled shRNA plasmid.
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MC3T3-E1 cells following knockdown of Fat4 and Dchs1.
However again, no detectable differences were observed
(Fig. S6). Finally, given that we had found a decrease in Taz
mRNA expression in Fat4−/− osteoblasts in vitro we carried out
RNAScope analyses to examine whether there are potential changes
in either the domains or levels of Taz mRNA expression in vivo.
This analysis did not identify any obvious changes (Fig. 7C and data
not shown) but did reveal that Taz mRNA is expressed throughout
the progenitor population, in contrast to the more restricted domain
of Taz protein expression (Fig. 7B). We also determined the
expression of Yap and found that Yap expression is highest in the
very early Runx2+veosterix−ve osteoprogenitors, in contrast to the
more restricted domain of Taz protein expression (Fig. 7B). In
Dchs1−/− mutants, the domain of Yap expression was expanded,
consistent with the expansion of the progenitor domain (Fig. 7A).
The above analyses revealed differential expression of Yap and
Taz: Yap is highest in a subpopulation of the Runx2+veosterix−ve
progenitors whereas Taz is highest in Runx2+veosterix+ve cells. Both
of these cell populations are proliferative. To analyse whether either
Yap or Taz regulate proliferation, wild-type calvarial cells were
transfected with a shRNA-Yap or shRNA-Taz vector and cells in S
phase were identified by a pulse of EdU. We found that cell
proliferation was significantly decreased by Yap, but not by Taz,
knockdown in wild-type osteoblasts (Fig. 6E; P<0.05). We then
determined whether the increased Yap activity in Fat4−/−
osteoblasts is responsible for the increased cell proliferation that
was observed. We found, however, that knockdown of Yap could
reduce but not rescue the increased proliferation in Fat4−/−
osteoblasts (Fig. 6E).
Dchs1-Fat4 regulation of Runx2 activity
In MC3T3 and Ros17/2.8 cell lines, Yap gain of function has been
shown to decrease activity of the Runx2-TGFβR1 reporter, have no
significant effect on the activity of the generic Runx2 promoter
6XOSE and enhance Runx2 inhibition of the Runx2-p21 promoter
(Zaidi et al., 2004). To first investigate whether the function of
Runx2 is controlled by Dchs1-Fat4 signalling, the activity of the
generic Runx2 (6XOSE, containing part of the Bglap promoter),
Runx2-p21, Runx2-TGFβR1 luciferase reporters was assessed in
wild-type, Fat4−/− and Dchs1−/− mutant primary calvaria
osteoblasts and the MC3T3-E1 cell line following knockdown of
Fat4 or Dchs1.We found that the activity of both the Runx2-p21 and
generic Runx2 reporters was significantly decreased in Fat4−/− and
Dchs1−/− primary cells (Fig. 8A and data not shown; Fat4+/+ n=3,
Fat4−/− n=6; p21, P <0.05; 6XOSE, P<0.01) and in the MC3T3-E1
cell line following knockdown of either Fat4 or Dchs1 (Fig. 8A;
control n=3, Fat4 shRNA n=3; p21 P<0.01; 6XOSE P<0.05; Dchs1
shRNA n=3, p21 P<0.05, 6XOSE P<0.05). Conversely, the activity
of the Runx2-TGFβR1 reporter is increased in mutant osteoblasts
and in the MC3T3-E1 cell line following knockdown of Fat4
(Fig. 8A; Fat4+/+ n=3, Fat4−/− n=3, P<0.05; MC3T3-E1 shRNA:
control n=3, Fat4 shRNA n=3, P<0.05). Therefore, Dchs1-Fat4
signalling differentially regulates the distinct Runx2 promoters. The
decreased activity of the Runx2-p21 promoter was also associated
with decreased p21 expression in MC3T3-E1 cells following
knockdown of Fat4 (Fig. 6F).
To determine whether increased Yap activity contributes to the
altered regulation of Runx2 promoter activity observed in Fat4−/−
osteoblasts, Yap expression was knocked down in Fat4−/−
osteoblasts and the effect on the activity of the three Runx2
reporters was analysed. This revealed that knockdown of Yap
significantly decreased Runx2-TGFβR1 reporter activity in both
wild-type and Fat4−/− cells but had no effect the 6XOSE and p21
promoters (Fig. 8B,C; Runx2-TGFβR1 P<0.05). Thus, increased
Yap is at least partly responsible for the increased activity of Runx2-
TGFβR1 reporter activity observed in Fat4−/− cells.
Although we did not detect any alterations in the levels of Taz
expression or Taz-Tead activity in the previous studies, the activity of
Taz can be qualitatively altered by post-transcriptional mechanisms
such as through distinct binding partners or phosphorylation.
To investigate whether Taz activity is also regulated by Dchs1-Fat4
signalling, Taz expression was knocked down in wild-type and
Fat4−/− osteoblasts and the activity of the three Runx2 reporters
was analysed. This revealed that Taz regulates the activity of the
p21 and 6XOSE reporters but does not control activity of the
TGFβR1 reporter in wild-type osteoblasts (Fig. 8B). Specifically,
knockdown of Taz decreases the activity of the generic Runx2 and
Runx2-p21 promoters in wild-type osteoblasts (Fig. 8B).
However, knockdown of Taz could not further decrease the
activity of these two reporters in mutant osteoblasts, potentially
indicating that the activity of Taz-Runx2 complexes is decreased
in Fat4−/− osteoblasts (Fig. 8C).
Fig. 7. Yap and Taz are differentially expressed within the developing
bone. (A,B) Immunolocalisation and RNAScope analyses showing the
expression of (A) Yap (yellow) and osterix (red), (B) Taz (red) proteins and
(C) Taz mRNA (red) in a palatine bone from wild-type and Dchs1−/− E16.5
embryos. In A the boxed region is shown at higher magnification in the image
below where the white lines indicate the bone boundary; the osteogenic
progenitors are located just inside the white lines; the nuclei are stained with
DAPI. In B, the borders of the bone and themineralised region of the bones are
demarcated by the white dashed and yellow dotted lines, respectively; the
osteogenic progenitors are located between the two lines. Nuclei are stained
with DAPI (blue). In C, the boundary between the osteocytes (upper part of
image) and osteogenic progenitors (lower part of image) is demarcated by
arrows; the red punctate staining indicates Taz mRNA. n=3 biological
replicates for each genotype in each analysis. Scale bars: 100 μm (A,B);
50 μm (C).
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DISCUSSION
Here, we have shown that Dchs1-Fat4 signalling regulates bone
development by controlling proliferation, survival and differentiation
within the osteogenic progenitors. Membrane bones of different
tissue origins, neural crest (frontal, palatine), cranial mesoderm
(parietal) and lateral plate mesoderm (bone collar of femur), are all
affected in both Dchs1 and Fat4 mutants showing a global role of
Dchs1-Fat4 signalling in intramembranous ossification. In Dchs1
mutants, the defects also encompassedmany aspects of endochondral
bone development. The abnormalities are consistent with the
craniofacial phenotype of Van Maldergem patients and could also
explain the increased susceptibility to fracture that has been reported
in some patients (Mansour et al., 2012). Therefore, we have identified
a new signalling pathway in bone development, together with
mechanisms of action, which have relevance to our understanding of
bone development and maintenance in humans.
At the cellular level, we identified that Dchs1-Fat4 controls two
key processes within the osteogenic progenitors, regulating both cell
proliferation and progression along the differentiation pathway. We
show that Yap activity is increased whereas Taz-Runx2 activity is
decreased. Both of these changes will contribute to the osteogenic
defects. Increased Yap activity has also been shown to inhibit
osteogenesis in the C3H10T1/2 cell line (Seo et al., 2013) and Taz is
essential for osteoblast differentiation (Cui et al., 2003; Hong et al.,
2005). At the molecular level these effects are mediated, in part, by
Yap/Taz regulation of Runx2 activity. Increased expression of Yap
targets, such as CTGF, which can increase osteoblast proliferation
and inhibit differentiation, may also contribute to the phenotype
(Mundy et al., 2014; Arnott et al., 2011). Additionally, at E18.5
there is also increased cell death within the osteogenic progenitors,
which would contribute to the defects in bone development. This
increased cell death may be secondary to altered cellular and
morphological behaviours, as has been observed in the kidney (Mao
et al., 2011, 2015), or paradoxically may be due to increased Yap
signalling. In hepatocytes, overexpression of Yap has been shown to
simultaneously promote both cell proliferation and cell death (Su
et al., 2015) and as alterations in cell death were not found at E15.5
and E16.5, a similar mechanism may occur in E18.5 bones.
The increased proliferation within the osteogenic progenitors is
analogous to the role of Dchs1-Fat4 signalling in the cerebral cortex
and heart (Cappello et al., 2013; Ragni et al., 2017) and in contrast
to the decreased proliferation observed in the kidney and somites
(Kuta et al., 2016; Mao et al., 2011). As in the heart and brain, loss
of Dchs1-Fat4 signalling also resulted in increased Yap activity. In
the cerebral cortex and heart, knockdown of Yap activity through
shRNA and genetic approaches was sufficient to fully rescue the
Fig. 8. Dchs1 and Fat4 regulate Runx2 activity. (A) Activity of the Runx2 reporters in primary Fat4+/+ and Fat4−/− calvarial osteoblast cells, and the MC3T3 cell
line in which Fat4 expression has been knocked down with shRNA constructs. (B,C) The effect of knockdown of Yap and Taz expression on Runx2 reporter
activity in wild-type (B) and Fat4−/− (C) osteoblasts. Data points indicate each independent biological experiment i.e. n≥3, each with 2-3 technical replicates.
Within each control group, the averagemeasurement was standardised to 1. scr, scrambled shRNA plasmid. (A, left-hand side,B,C) Unpaired two-tailed Student’s
t-tests. (A, right-hand side) One-way ANOVA (significance in purple) for multiple comparisons using post-hoc Dunnett’s test (significance in black) *P<0.05;
**P<0.01. ns, not significant. Error bars represent s.e.m.
9
RESEARCH ARTICLE Development (2019) 146, dev176776. doi:10.1242/dev.176776
D
E
V
E
LO
P
M
E
N
T
increased proliferation observed in Fat4 mutants (Cappello et al.,
2013; Ragni et al., 2017). In contrast, knockdown of Yap within the
osteogenic progenitors, although decreasing proliferation, did not
rescue the increased proliferation observed in Fat4−/− cells. This
may be due to a partial Yap knockdown and/or indicate that Dchs1-
Fat4 regulate cell proliferation via Yap-independent mechanisms.
However, Yap knockdown did result in a significant reduction in
proliferation in wild-type osteoblasts. Therefore, at this point,
although we cannot attribute the increased proliferation in Fat4−/−
osteoblasts to a Yap-dependent mechanism as has been observed in
the heart and brain (Cappello et al., 2013; Ragni et al., 2017), we can
definitively conclude that Yap is the major regulator of cell
proliferation within wild-type osteoblasts and that, in contrast, Taz
does not have a major proliferative role.
Our data additionally highlight the differential roles of Yap and
Taz, which are often assumed to act redundantly. Within
osteoblasts, Yap, but not Taz, has Tead-dependent activities.
Teads are the main transcriptional binding partners for Yap and
Taz and the ‘Hippo’ reporter measures Yap-Tead or Taz-Tead
activity (Ehmer and Sage, 2016; Hansen et al., 2015). Our data
indicate that Yap, but not Taz, has Tead-dependent activities within
osteoblasts. Knockdown of Yap reduces ‘Hippo-Tead’ reporter
activity in wild-type and Fat4 mutant osteoblasts whereas Taz
knockdown has minimal effect. Therefore, within developing
osteoblasts Taz must mediate its functions via other transcriptional
partners independently of Teads.
One candidate transcriptional partner is Runx2. Previous studies
have shown that Taz and Yap have distinct effects on the activity of
Runx2 (Cui et al., 2003; Hong et al., 2005; Zaidi et al., 2004).
During this study, we have also extended previous analyses to show
that Taz regulates the p21-Runx2 reporter. Yap can be inhibitory for
osteogenesis (Seo et al., 2013) whereas Taz is required and
sufficient to drive osteogenic differentiation (Hong et al., 2005;
Yang et al., 2013). Therefore, within developing osteoblasts, it is
essential that their expression and/or activity are uncoupled. We
show that Yap regulates the Runx2-TGFβR1 but not the p21-Runx2
or generic Runx2 reporters. Specifically, we found that increased
Yap in Fat4−/− osteoblasts enhances Runx2-TGFβR1 reporter
activity. These data differ from a previous study which indicated that
Src-phosphorylated Yap (on tyrosine residues) inhibits Runx2
activation of the Runx2-TGFβR1 reporter and increases Runx2
suppression of the p21 promoter (Zaidi et al., 2004). This difference
may be due to the use of osteoblasts of different origin or that
tyrosine-phosphorylation of Yap is altered by Dchs1-Fat4
signalling.
Our data also indicate that Taz-Runx2 transcriptional activity is
decreased in Dchs1−/− and Fat4−/− osteoblasts. First, the activity of
the Runx2-p21 and generic Runx2 6XOSE reporters, which are
regulated by Taz in wild-type cells, is decreased following loss or
knockdown of Dchs1-Fat4 signalling. Second, knockdown of Taz
in Fat4−/−mutant cells did not decrease reporter activity further. As
levels of total Taz are unchanged, how this occurs is currently
unclear. Potential mechanisms include changes in Taz binding to its
potential co-transcriptional partners, or by the differential
recruitment of proteins to the Taz-Runx2 transcriptional complex
and/or by influencing the intracellular localisation of Taz.
The differential roles of Yap and Taz reflect their distinct
expression patterns. Yap is expressed in the early osteoblast
progenitors whereas Taz expression is more restricted within a
population of more-differentiated osteoblasts adjacent to the
mineralisation front. Of note, Yap and Taz expression was
predominantly cytoplasmic with very low levels of Yap within
the nuclei and the immunolocalisation studies revealed no striking
changes in Yap and Taz intracellular localisation in mutant
osteoblasts. However, this does not indicate that Yap and Taz are
inactive as Yap activity was clearly detected, and shown to be
altered in mutant osteoblasts, by the more sensitive luciferase
reporter assays and qPCR analysis of Yap/Taz targets, Ctgf, Cyr61
and Ankrd1, with the potential caveat that these genes are also
regulated by other signalling pathways. This predominantly
cytoplasmic localisation of Yap has also been observed in
postnatal trabecular osteoblasts where Yap controls proliferation
(Pan et al., 2018). Also, levels of Yap can determine distinct cellular
outputs, e.g. osteoblast versus adipocytes, and, therefore, a
cytoplasmic bias in localisation does not indicate a lack of activity
(Seo et al., 2013). The expression analyses also indicated that Taz
protein and mRNA expression are uncoupled: Taz mRNA is found
throughout the proliferative osteogenic progenitors in contrast to
the more restricted protein expression domain. Therefore,
within the osteoblast progenitors, Taz activity is controlled by
post-translational mechanisms such as proteosomal degradation.
Although Fat4 signalling via Dchs2 has also been reported in the
kidney (Bagherie-Lachidan et al., 2015), Fat4-Dchs1 typically act as
a ligand-receptor pair. The craniofacial phenotypes are identical in
the Fat4 andDchs1mutants, leading us to believe that here they also
act as a ligand-receptor pair within the osteogenic progenitors
during bone development. However, deletion of Dchs1, but not
Fat4, within the differentiated osteoblasts [mediated via the
osteocalcin (Bglap) Cre] resulted in a comparably minor
craniofacial bone phenotype. Likewise, trabecular defects were
also observed in the endochondrally derived femur bones of Dchs1,
but not Fat4, mutants. This may indicate that Dchs1 acts through
another Fat receptor such as Fat1, which can control Yap activity in
fibroblasts (Martin et al., 2018). Alternatively there may be slight
variations in the genetic background of the mutant mice. Within the
Bglap-expressing cells it is also possible that Dchs1 in the more
differentiated osteoblasts signals back to less-differentiated Fat4-
expressing cells to drive osteogenic progression.
We have shown that Dchs1-Fat4 exert intrinsic control of bone
development within osteoblast progenitors via regulation of cell
proliferation, survival and Runx2 activity. Runx2 is the pivotal
player during osteoblast development; it regulates osteoblast
commitment, proliferation and ultimately progression along the
osteogenic lineage to terminal differentiation (Komori, 2011; Long,
2011; Westendorf et al., 2002). Hence, levels of Runx2 expression
and activity are finely tuned by the precise integration of a diverse
array of signalling pathways, many of which impinge on Yap and
Taz, which are also crucial regulators of osteogenesis. Thus, we
have identified another osteogenic signalling pathway and shown at
a cellular and molecular level how Dchs1-Fat4 signalling regulates
osteoblast development. Crucially, the Fat4 and Dchs1 mutants
phenocopy many aspects of VanMaldergem syndrome and thus our
data provide a model and the foundations for understanding how
this little-understood pathway regulates bone development and
maintenance in humans.
MATERIALS AND METHODS
Mice
The mouse lines used were: Dchs1+/− and Dchs1fl/fl (Mao et al., 2011),
Fat4+/− and Fat4fl/fl (Saburi et al., 2008), Yap+/− (Mao et al., 2015) and
Taz+/− (Wwtr1) (Hossain et al., 2007), Mesp1-Cre (Saga et al., 1999),
Dermo1-Cre (Yu et al., 2003), and osteocalcin-Cre (Bglap OC-Cre; Zhang
et al., 2002). Dchs1, Fat4 and all the Cre lines were maintained on a C57Bl/
6J background whereas all fl/fl mice were maintained on a 129/SV
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background. P0 and embryos for analysis were generated from the
appropriate crosses. The day of the mouse plug was assigned E0.5.
All mouse procedures were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) at Rutgers University or the Use
Committee of King’s College (London, UK) under UK Home Office
regulations; animal licence PPL 70/7328.
µ-CT analysis
Whole skulls and limbs from neonatal mice were µ-CT scanned
(Skyscan1172 high-resolution μ-CT, Bruker, RVC, London). For all
scans, calibration hydroxyapatite phantoms (Skyscan, Bruker) were used
to facilitate conversion of the linear attenuation of a given voxel to mg HA/
cm3. Skulls, individual bones within the skull (frontal, parietal, interparietal,
palatine and mandible) and limbs (femur) were manually isolated,
segmented, 3D reconstructed, and visualised using Brucker Software
(NRecon, DATAVIEWER, CT-An and CT-Vox from Skyscan, Brucker)
following manufacturer protocols and specifications. For the femur analysis,
different volumes of interest (VOIs) were defined in the trabecular region,
excluding the cortical shell, at mid-shaft (diaphysis, 50% of bone length)
and distal (metaphysis, 33% of bone length) regions. For the femur, the
following parameters were determined: bone volume fraction (BV/TV),
cortical thickness and trabecular number. The size and bone mineral density
were measured for the whole skull and the individual bones, applying the
same thresholds for each litter to separate higher density bone from soft
tissues and air. The selected VOIs were analysed using CT-An BatMan
software (Skyscan, Kontich, Belgium) and 2D/3D morphometric
parameters were recorded. In some CT scans, background ‘noise/dots’
between the bones in the CT scans has been removed for clarity.
Cell culture and reporter assays
Primary osteoblasts from neonatal mouse calvaria (frontal and parietal
bones) were isolated and cultured as described by Taylor et al. (2014).
Specifically, isolated individual calvaria were sequentially digested (at
37οC) for 10 min in 0.25% trypsin-EDTA (Sigma-Aldrich, T4049), 30 min
in 0.2% collagenase (Sigma-Aldrich, C9891), with a final digestion in 0.2%
collagenase for 1 h. The osteoblast cells were passaged for 2-4 days in
growth media (Gibco, 10270-106) with 2 mM L-glutamine (AB/AM) and
were then seeded at a density of 1.5×104 cells/well in 24-well plates
and cultured in differentiation media (growth media with 10 mM
β-glycerophosphate and 50 µg/ml ascorbic acid).
For the luciferase reporter assays, primary cells and the mouse osteoblast
cell line MC3T3-E1 (ATCC CRL-2593, same media as primary cultures)
were used. Cells were seeded at 1.5×104 cells/well in 24-well plates. On day
2-3 of culture, 250 ng of the reporter plasmid or shRNAvector together with
50 ng of Renilla plasmid were transfected into the primary osteoblasts or the
MC3T3-E1 cell line using Lipofectamine LTX with Plus Reagent kit
(Invitrogen, 15338-100) conforming to manufacturer instructions. The
Renilla plasmid was used as an internal control to standardise the
transfection efficiency. Luciferase reporter assays were carried out with
Dual-Luciferase Reporter (DLR) Assay System (Promega, E1910) 48 h
after lipofection; two or three technical replicates per experiment were
measured and averaged. Each assay was repeated at least three times. Cell
lines were tested for any mycoplasma contamination every 4 weeks.
Plasmids
Yap-Tead luciferase reporter, and its control reporter (Schlegelmilch et al.,
2011), the Runx2 luciferase reporter plasmids (6XOSE, containing
multimerised Runx2-binding sites), p21 or TGFβR1 (Zaidi et al., 2004),
Dchs1, Fat4 or control siRNA (Cappello et al., 2013), Taz (Wwtr1,
NM_133784, TRCN0000095951) and Yap (Yap1, NM_009534,
TRCN0000238432) were obtained from MISSION shRNA library
(Sigma-Aldrich).
qPCR
RNA was extracted from cultured cells using the RNeasy Micro Kit
(Qiagen) and reverse transcribed to cDNAs with GoScript Kit (Promega).
Quantitative PCR was carried out using Fast Start SYBR Green Master
(Roche) on a Bio-Rad CFX 384 (Bio-Rad) machine. Relative gene
expression was quantified by the standard curve method using B2M as a
control housekeeping gene. Primer sequences were: B2M forward CTGC-
TACGTAACACAGTTCCACCC, B2M reverse CATGATGCTTGATCA-
CATGTCTCG; TAZ forward CCATCACTAATAATAGCTCAGATC, TAZ
reverse GTGATTACAGCCAGGTTAGAAAG; YAP forward CGGCAG-
GCAATGCGGAATATCAAT, YAP reverse ACCATCCTGCTCCAGTG-
TTGGTAA; p21 forward GCCTTAGCCCTCACTCTGTG, p21 reverse
AGGGCCCTACCGTCCTACTA; Bglap forward CCGGGAGCAGTGT-
GAGCTTA, Bglap reverse TAGATGCGTTTGTAGGCGGTC; Ctgf,
forward GACCCAACTATGATGCGAGCC, Ctgf reverse CCCATCCCA-
CAGGTCTTAGAAC; Cyr61 forward AGAGGCTTCCTGTCTTTGGC,
Cyr61 reverse CCAAGACGTGGTCTGAACGA; Ankrd forward TGCG-
ATGAGTATAAACGGACG, Ankrd reverse GTGGATTCAAGCATA-
TCTCGGAA.
RNAScope
Formalin-fixed paraffin-embedded samples were analysed with RNAScope
2.5 assay (Advanced Cell Diagnostic) using a RNAScope 2.5 HD-Red kit
(Wang et al. 2012). Samples were cut at 5 µm thickness and processed
according to manufacturer’s recommendations. Freshly cut sections were
incubated in a hybridisation oven for 1 h at 60°C and subsequently
deparaffinised. The slides were treated with hydrogen peroxide solution for
10 min at room temperature. For E16.5 embryos, the standard pre-treatment
recommendations were followed. Samples were boiled in target retrieval
solution for 15 min keeping the temperature between 98 and 102°C. After
30 min incubation at 40°C with protease plus reagent, sections were
hybridised with the following probes for 2 h at 40°C: WWTR1 (Taz), PPIB
(positive control), and DapB (negative control), all from Advanced Cell
Diagnostics. Sections were then incubated with the signal amplification
solutions in the following order: amp1 for 30 min at 40°C, amp2 for 15 min
at 40°C, amp3 for 30 min at 40°C, amp4 for 15 min at 40°C, amp5 for
30 min at room temperature, amp6 for 15 min at room temperature. Finally,
slides were incubated with Fast Red solution for 10 min at room temperature
to detect the signal. Samples were counterstained with Gill’s Hematoxylin I
and mounted using VectaMount mounting medium (Vector labs). The
results were analysed with a standard brightfield microscope (Zeiss
Axioskop with a Nikon DS-Fi2 camera) at 40× magnification.
Whole-mount and in vivo skeletal analysis
Alcian Blue and Alizarin Red staining of P0 pups, E15.5 and E16.5 heads
was performed to analyse bone development. Bone deposition and
resorption were also evaluated by intraperitoneal injections of calcein
(Sigma-Aldrich, C0875; 2.5 mg/kg body weight) into pregnant females at
E15.5 and Alizarin Complexone (Sigma-Aldrich, a3882; 7.5 mg/kg) at
E16.5. The calvarias were collected 2 h after the Alizarin Complexone
injection and fixed overnight in 4% paraformaldehyde (PFA) in PBS. They
were washed in PBS and flat-mounted for imaging by confocal microscopy
using a Leica SP5 confocal microscope.
Histological and immunolocalisation assays
Embryos were dissected in cold PBS (RNAse free), fixed overnight in 4%
PFA at 4οC and dehydrated through an increasing series of alcohols (50, 70,
80, 85, 90, 95% and absolute ethanol) and embedded in paraffin. Frontal
sections (10-12 µm) were mounted and used for in situ hybridisation,
immunostaining or chemical staining. One mutant embryo paired with one
control littermate were processed together and mounted on the same slides.
To determine alkaline phosphatase activity, sections were incubated in NMT
buffer (100 mM Tris HCl pH 9.5, 50 mM MgCl2, 100 mM NaCl) with 5-
bromo-4-chloro-3-indolyl-phosphate (BCIP; 3.4 µl/ml; Roche,
11383221001) and 4-nitro blue tetrazolium (NBT; 4.5 µl/ml; Roche,
11383213001) for 12 min at room temperature in the dark. To determine
levels of mineralisation, sections were stained in Alizarin Red solution (pH
4.2, 2% 3,4-dihydroxy-9,10-dioxo-2-anthracenesulfonic acid sodium salt,
Sigma-Aldrich, A3757, in distilled H2O) for 5-8 min. TRAP activity was
determined on 10 µm PFA-fixed sections using a leucocyte acid
phosphatase (Trap) kit (Sigma-Aldrich, 387A 1KT).
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For immunostaining, de-waxed slides were treated in antigen retrieval
buffer (10 mM citric acid pH 6.4) in a pressure cooker for 6.5 min. Sections
were blocked in 2% bovine serum albumin, 5% goat serum, for 30 min at
room temperature in a humid chamber and then counterstained with 1%
Sudan Black B (Sigma-Aldrich, 199664) to reduce autofluorescence. For
Runx2 immunostaining, a biotin amplification step using biotinylated goat
anti-mouse IgG antibody (Vectashield, BA-9200) and Streptavidin 488
(Biolegend, 405235) was carried out. For Yap and Taz immunostaining, a
PerkinElmer TSACyanine 3 System (NEL704A001KT) was used. Primary
mouse osteoblast cells plated on glass coverslips were fixed in 4% PFA for
20 min, washed in PBS, blocked and immunostained. The following
primary antibodies were used: Runx2 (Abcam, ab76956, 1:100), osterix
(Abcam, ab22552, 1:1000), caspase 3 (Cell Signaling Technology, 9661S,
1:200), Bglap (Santa Cruz Biotechnology, sc-30045, 1:100), Yap (Santa
Cruz Biotechnology, sc-101199; 1.1000), Taz (Atlas, HPA007415,
1:2000). The secondary antibodies were donkey anti-mouse 594
(Invitrogen, A21203, 1:500), donkey anti-rabbit 488 (Invitrogen, A21206,
1:500), donkey anti-rabbit 568 (Invitrogen, A10042, 1:500). Sections/cells
were counterstained with DAPI.
In situ hybridisation
In situ hybridisation to tissue sections was carried out as described by Mao
et al. (2011) using [50% formamide, 5× SSC, 50 µg/ml heparin (Sigma-
Aldrich, H3393), 50 mg/ml total yeast RNA, 50 µg/ml SSDNA (Invitrogen,
15632-011) and 0.1% SDS] for prehybridisation at 65οC for 2 h. Sections
were incubated overnight with the corresponding digoxigenin (DIG)-
labelled antisense RNA probe in hybridisation buffer (pre-hybridisation
buffer without total yeast RNA). Unbound probe was removed by washing
at increasing stringency: 62οC (two 30 min washes in 50% formamide, 5×
SSC, 1% SDS) and 60οC (two 30 min washes in 50% formamide, 2× SSC,
0.2% SDS). Slides were washed in MABT solution (maleic acid buffer
containing 0.1% Tween 20) and blocked in 10% sheep serum for 1 h before
incubating overnight at 4οC with anti-DIG antibody (1:2000 dilution).
Unbound antibody was removed by six washes in PBST (PBS containing
0.1% Tween 20; 8 min, rocking) at room temperature. Bound probe was
visualised by staining with NBT/BCIP at pH 9.5 in NMT buffer (see above).
The following probes were used: Dchs1 (Mao et al., 2011), Fat4 (Mao et al.,
2011), Bglap (Lana-Elola et al., 2007), osteopontin (Young et al., 1990).
Proliferation and cell counting analyses
To label cells in the S phase of the cell cycle pregnant females were injected
intraperitoneally with EdU (200 mg/kg) at a gestation age of E15.5 and E16.5.
Embryos were collected 4 h later and processed for immunolocalisation
analyses. For primary cell cultures, cells were plated onto glass coverslips and
pulsed with 20 µM EdU for 2 h. Cells were then washed in PBS and fixed in
4%PFA for 10 min. EdU-labelled cells were detectedwith Click-iT Plus EdU
Alexa Fluor 594 Imaging Kit (Molecular Probes, C10639) following the
manufacturer’s protocol. Alternatively, cells undergoing mitosis were
identified by immunostaining for phospho-histone H3 (Cell Signaling
Technology, 9706L, 1:500).
Following immunostaining, cells from confocal images (20× objective)
were manually counted using ImageJ software (Rasband, W.S., ImageJ,
U. S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej.
nih.gov/ij/, 1997-2016) from at least six sections per embryo or at least five
different microscopic fields within a primary culture.
Western blot analysis
Western blot analysis was carried out on total proteins extracted from cell
cultures (MC3T3 E1) 48 h after transfection with either scrambled control
(scr) or Dchs1 shRNA or Fat4 shRNA, using Passive Lysis 5X buffer
(Promega, E194A), and on liver tissue from wild-type or Taz−/− adult mice
using RIPA lysis buffer (150 mMNaCl, 1% NP-40, 0.5% DOC, 0.1% SDS,
50 mM Tris pH 7.4), which included a protease and phosphatase inhibitor
cocktail. Protein concentration was measured at 560 nm using a BCA
protein assay kit (Novagen, 71258) according to manufacturer’s
recommendations. Lysates (10 µg) of prepared in Laemmli Buffer (Bio-
Rad, 1610747) were boiled at 95°C for 5 min and then resolved by SDS-
PAGE. Proteins were transferred onto PVDF membranes using a Trans-blot
Turbo transfer system (Bio-Rad) and blocked with 5% non-fat milk for 1 h at
room temperature. Membranes were incubated overnight at 4°C with the
primary antibodies anti-WWTR1 (1:1000, Atlas, HPA007415) and anti-
cyclophilin B, the loading control (1:1000, R&D Systems, MAB5410),
followed by incubation with the anti-mouse or anti-rabbit HRP-conjugated
secondary antibodies (1:2000, Dako, P0448 and P0447). Proteins of interest
were detected with an ECL substrate (Bio-Rad, 1705060) and imaged with
Chemidoc Imaging system (Bio-Rad). Densitometric analysis was carried
out using ImageJ software and the signal of the protein of interest was
normalised to the loading control.
Statistical analysis
To compare and standardise the results, the average value for wild-type or
controls was normalised to 1. The wild-type, heterozygote, mutant or
control/experimental value were then standardised as a ratio of the average
wild-type number. All stated numbers (n) are for different biological
replicates (either in vivo or in vitro). For the cell culture experiments, at least
three technical replicates were analysed and the average used. The
significance of the data was determined using unpaired Student’s t-test
comparing control/experimental or wild type/mutant pairs. Each data pair
was analysed individually. Within the graphs, the control bar combines the
individual control values from each data set. Sample size, n=3-5. No
samples or datasets were excluded from the analyses.
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